Organic Letters
Letter
a
(8) Stazi, F.; Maton, W.; Castoldi, D.; Westerduin, P.; Curcuruto, O.;
Bacchi, S. Synthesis 2010, 3332.
Scheme 7. One-Pot Formation of Arylacetonitrile 12l
(9) Kosugi, M.; Ishiguro, M.; Negishi, Y.; Sano, H.; Migita, T. Chem.
Lett. 1984, 1511.
(10) (a) Frejd, T.; Klingstedt, T. Synthesis 1987, 40. (b) Yang, Y.; Tang,
S.; Liu, C.; Zhang, H.; Suna, Z.; Lei, A. Org. Biomol. Chem. 2011, 9, 5343.
(11) (a) Wu, L.; Hartwig, J. F. J. Am. Chem. Soc. 2005, 127, 15824.
(b) Culkin, D. A.; Hartwig, J. F. J. Am. Chem. Soc. 2002, 124, 9330.
(12) Shang, R.; Ji, D.-S.; Chu, L.; Fu, Y.; Liu, L. Angew. Chem., Int. Ed.
2011, 50, 4470. For a related intramolecular decarboxylative α-allylation
reaction of nitriles, see: Recio, A., III; Tunge, J. A. Org. Lett. 2009, 11,
5630.
a
Reactions performed in sealed vials.
(13) Wu, G.; Deng, Y.; Wu, C.; Zhang, Y.; Wang, J. Angew. Chem., Int.
Ed. 2014, 53, 10510.
(14) Velcicky, J.; Soicke, A.; Steiner, R.; Schmalz, H.-G. J. Am. Chem.
Soc. 2011, 133, 6948.
(15) For the preparation of methyl 4-bromo-5-methylisoxazole-3-
carboxylate (2), see: Imanshi, Y.; Awai, N.; Hirai, M.; Hosaka, T.; Kono,
R. Patent Appl. 037271, 2005.
(16) For examples of the decarboxylative opening of isoxazoles, see:
(a) Zhoua, P.; Natalea, N. R. Synth. Commun. 1998, 28, 3317. (b) Perez,
C.; Janin, Y. L.; Grierson, D. S. Tetrahedron 1996, 52, 987. (c) Ciller, J.
A.; Seoane, C.; Soto, J. L. Heterocycles 1984, 22, 1989.
(17) In some cases, compound 9 was observed in the crude reaction
mixtures and it was not always possible to separate this from the
products. The amount of 9 was quantified by analysis of the 1H NMR
spectra, and the mixture of compounds was taken through into the
isoxazole deprotection step.
In summary, we have developed a two-step cyanomethylation
protocol whereby bromoisoxazole 2 was shown to couple
effectively with potassium aryltrifluoroborate salts to give aryl
isoxazoles that were deprotected to give the target α-aryl nitriles.
Notably, five heteroarylacetonitriles were also accessed via their
corresponding heteroarylstannanes, offering considerable ad-
vantage over existing cyanomethylation methodologies. The
cross-coupled isoxazole intermediates were also shown to be
amenable to functionalization prior to deprotection, allowing
facile access to challenging molecular scaffolds bearing two
differently substituted cyanomethylene units.
ASSOCIATED CONTENT
* Supporting Information
■
S
Experimental procedures and compound characterization. This
material is available free of charge via the Internet at http://pubs.
(18) Molander, G. A.; Canturk, B.; Kennedy, L. E. J. Org. Chem. 2009,
74, 973.
(19) SPhos-Pd G2 = chloro(2-dicyclohexylphosphino-2′,6′-dime-
thoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) and
XPhos-Pd G2 = chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-
1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II).
(20) Littke, A. F.; Schwarz, L.; Fu, G. C. J. Am. Chem. Soc. 2002, 124,
6343.
AUTHOR INFORMATION
Corresponding Author
■
(21) The enzymatic hydrolysis of 1,3-phenylenediacetonitrile has
previously been reported: Cohen, M. A.; Sawden, J.; Turner, N. J.
Tetrahedron Lett. 1990, 31, 7223.
Notes
The authors declare no competing financial interest.
(22) For the oxidative decyanation of diphenylacetonitriles, see: Kulp,
S. S.; McGee, M. J. J. Org. Chem. 1983, 48, 4097.
ACKNOWLEDGMENTS
We thank Christopher Reutter (Eli Lilly) for his assistance with
high resolution mass spectrometry samples.
■
REFERENCES
■
(1) Bordwell, F. G.; Bares, J. E.; Bartmess, J. E.; McCollum, G. J.; van
der Puy, M.; Vanier, N. R.; Matthews, W. S. J. Org. Chem. 1977, 42, 321.
(2) (a) Kukushkin, V. Y.; Pombeiro, A. J. L. Inorg. Chim. Acta 2005,
358, 1. (b) Trivedi, B. K.; Holmes, A.; Stoeber, T. L.; Blankey, C. J.;
Roark, W. H.; Picard, J. A.; Shaw, M. K.; Essenburg, A. D.; Stanfield, R.
L.; Krause, B. R. J. Med. Chem. 1993, 36, 3300. (c) Xi, F.; Kamal, F.;
Schenerman, M. A. Tetrahedron Lett. 2002, 43, 1395. (d) Weiberth, F. J.;
Hall, S. S. J. Org. Chem. 1987, 52, 3901.
(3) Friedrich, K.; Wallenfels, K. The Chemistry of the Cyano Group;
Wiley-Interscience: New York, 1970.
(4) (a) Milani, M.; Jha, G.; Potter, D. A. Clin. Med. Ther. 2009, 1, 141.
(b) Cooper-DeHoff, R. M.; Handberg, E. M.; Mancia, G.; Zhou, Q.;
Champion, A.; Legler, U. F.; Pepine, C. J. Expert Rev. Cardiovasc. Ther.
2009, 7, 1329. (c) Brogden, R. N.; Benfield, P. Drugs 1994, 47, 93. (d)
For a review of nitrile groups in pharmaceuticals, see: Fleming, F. F.;
Yao, L.; Ravikumar, P. C.; Funk, L.; Shook, B. C. J. Med. Chem. 2010, 53,
7902.
(5) (a) Soli, E. D.; Manoso, A. S.; Patterson, M. C.; Deshong, P.; Favor,
D. A.; Hirschmann, R.; Smith, A. B., III. J. Org. Chem. 1999, 64, 3171.
(b) Chen, G.; Wang, Z.; Wu, J.; Ding, K. Org. Lett. 2008, 10, 4573.
(6) (a) Yoshida, H.; Fujimura, Y.; Yuzawa, H.; Kumagaia, J.; Yoshidab,
T. Chem. Commun. 2013, 49, 3793. (b) Kurz, M. E.; Lapin, S. C.;
Mariam, A.; Hagen, T. J.; Qian, X. Q. J. Org. Chem. 1984, 49, 2728.
(7) Narsaiah, A. V.; Nagaiah, K. Adv. Synth. Catal. 2004, 346, 1271.
D
Org. Lett. XXXX, XXX, XXX−XXX